Howdy Entdoc – appreciate you joining us. I always enjoyed reading your analysis of Peregrine’s pipeline over on RB back in the days, and hope you’ll stick around and post often here.
Interesting, Chemo-Only results… I’ve gone back thru my Avastin vs. Bavi chemo-combo comparison trials ( http://tinyurl.com/oz3fhv ), but I didn’t see and chemo-only figures referenced in them (not saying I couldn’t have missed them).
I did find a 2004 article from The Oncologist, “Docetaxel & Paclitaxel in the Treatment of Breast Cancer: A Review of Clinical Experience”, and it’s loaded, but comparing those populations of “metastatic and early-stage breast cancer” to what Bavi & Avastin are/were treating, I’ll have to leave to somebody more qualified than myself. http://theoncologist.alphamedpress.org/cgi/content/full/9/suppl_2/24
If this helps, I do recall that CFO Paul Lytle, in his 3-18-09 talk at the Cowen Healthcare Conf. ( http://tinyurl.com/cal9br ), showed 2 Chemo-Only ORR% references in his MBC Bavi+CP vs. SOC slide #13 – he called them “Best Response Reported”: • CP (Fountzilas), 53% ORR (35 of 66) – best resp. reported. [ 1998 Ph2 http://tinyurl.com/d8g8fu ] • CP (Perez), 62% ORR (33 of 53) – best resp. reported. [ 2000 Ph2 http://tinyurl.com/cxk8yh ]
Market Data 
Markets 
AI
